Mechanisms of resistance likely include specific tumor-cell genetics (loss-of-function mutations in JAK1/2 [107]), and differing expression levels of tumor-cell surface proteins (e.g., MHC I expression [108], alternate ICIs [109], and epigenetic T-cell changes limiting effector function and memory [110]). Here, JAK1 is linked to neoplasm.